Reports Q2 revenue $1.11M vs $1.24M last year. Eric A. Adams, InMed’s Chief Executive Officer, commented, “We are pleased with the steady progress across both our pharmaceutical pipeline and commercial operations. The compelling data from INM-901’s preclinical study demonstrated a significant reduction in neuroinflammatory markers-a key contributor to Alzheimer’s disease progression. This positions INM-901 as an innovative approach targeting neuroinflammation, extending beyond traditional amyloid beta and tau-focused therapies. Additionally, the selection of an intravitreal formulation for INM-089 marks a critical milestone in advancing our dry AMD program, offering new possibilities for treatment delivery.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INM:
- InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation
- InMed Pharmaceuticals announces INM-089 IVT formulation as drug candidate
- Biotech Alert: Searches spiking for these stocks today
- InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs
- InMed Pharmaceuticals granted an international PCT patent